Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic
Proceedings of the National Academy of Sciences, 2008•National Acad Sciences
Each year, approximately five million people die worldwide from putatively vaccine-
preventable mucosally transmitted diseases. With respect to mass vaccination campaigns,
one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers
potential safety, logistical, and cost-saving advantages over traditional vaccination routes.
Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could
contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic …
preventable mucosally transmitted diseases. With respect to mass vaccination campaigns,
one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers
potential safety, logistical, and cost-saving advantages over traditional vaccination routes.
Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could
contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic …
Each year, approximately five million people die worldwide from putatively vaccine-preventable mucosally transmitted diseases. With respect to mass vaccination campaigns, one strategy to cope with this formidable challenge is aerosol vaccine delivery, which offers potential safety, logistical, and cost-saving advantages over traditional vaccination routes. Additionally, aerosol vaccination may elicit pivotal mucosal immune responses that could contain or eliminate mucosally transmitted pathogens in a preventative or therapeutic vaccine context. In this current preclinical non-human primate investigation, we demonstrate the feasibility of aerosol vaccination with the recombinant poxvirus-based vaccine vectors NYVAC and MVA. Real-time in vivo scintigraphy experiments with radiolabeled, aerosol-administered NYVAC-C (Clade C, HIV-1 vaccine) and MVA-HPV vaccines revealed consistent mucosal delivery to the respiratory tract. Furthermore, aerosol delivery of the vaccines was safe, inducing no vaccine-associated pathology, in particular in the brain and lungs, and was immunogenic. Administration of a DNA-C/NYVAC-C prime/boost regime resulted in both systemic and anal-genital HIV-specific immune responses that were still detectable 5 months after immunization. Thus, aerosol vaccination with NYVAC and MVA vectored vaccines constitutes a tool for large-scale vaccine efforts against mucosally transmitted pathogens.
National Acad Sciences